| Inbound Relationships |
Type |
Active |
Source |
Characteristic |
Refinability |
Group |
| Aromatic ammonia spirit (substance) |
Is a |
True |
Stimulant (substance) |
Inferred relationship |
Some |
|
| Pipradrol |
Is a |
False |
Stimulant (substance) |
Inferred relationship |
Some |
|
| Deanol |
Is a |
False |
Stimulant (substance) |
Inferred relationship |
Some |
|
| Pyrovalerone |
Is a |
False |
Stimulant (substance) |
Inferred relationship |
Some |
|
| Fencamfamin |
Is a |
False |
Stimulant (substance) |
Inferred relationship |
Some |
|
| Muskelstimulerende middel |
Is a |
False |
Stimulant (substance) |
Inferred relationship |
Some |
|
| Amphetamin |
Is a |
False |
Stimulant (substance) |
Inferred relationship |
Some |
|
| Analeptisk middel |
Is a |
False |
Stimulant (substance) |
Inferred relationship |
Some |
|
| stimulerende middel |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Stimulant (substance) |
Inferred relationship |
Some |
|
| Product containing modafinil (medicinal product) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Stimulant (substance) |
Inferred relationship |
Some |
|
| Product containing amfetamine (medicinal product) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Stimulant (substance) |
Inferred relationship |
Some |
|
| Caffeine solution |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Stimulant (substance) |
Inferred relationship |
Some |
|
| Weak central nervous system stimulants |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Stimulant (substance) |
Inferred relationship |
Some |
|
| Weak central nervous system stimulant+vitamins |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Stimulant (substance) |
Inferred relationship |
Some |
|
| Amphetamine and cocaine |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Stimulant (substance) |
Inferred relationship |
Some |
|
| Drugs used to treat hyperactivity disorders |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Stimulant (substance) |
Inferred relationship |
Some |
|
| Other central nervous system stimulants |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Stimulant (substance) |
Inferred relationship |
Some |
|
| Modafinil 100 mg oral tablet |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Stimulant (substance) |
Inferred relationship |
Some |
|
| middel med stimulerende virkning på centralnervesystemet |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Stimulant (substance) |
Inferred relationship |
Some |
|
| caffein 5 mg/ml injektionsvæske, opløsning, hætteglas a 2 ml |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Stimulant (substance) |
Inferred relationship |
Some |
|
| amfetamin eller psykostimulerende middel |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Stimulant (substance) |
Inferred relationship |
Some |
|
| phenterminhydrochlorid 30 mg kapsel med modificeret udløsning |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Stimulant (substance) |
Inferred relationship |
Some |
|
| Phentermine hydrochloride 30 mg oral capsule |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Stimulant (substance) |
Inferred relationship |
Some |
|
| caffeincitrat 20 mg/ml injektionsvæske, opløsning, ampul |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Stimulant (substance) |
Inferred relationship |
Some |
|
| Product containing precisely phentermine hydrochloride 18.75 milligram/1 each conventional release oral capsule (clinical drug) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Stimulant (substance) |
Inferred relationship |
Some |
|
| Caffeine citrate 20mg solution |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Stimulant (substance) |
Inferred relationship |
Some |
|
| Phentermine hydrochloride 8 mg oral tablet |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Stimulant (substance) |
Inferred relationship |
Some |
|
| Pemoline 18.75 mg oral tablet |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Stimulant (substance) |
Inferred relationship |
Some |
|
| Pemoline 37.5 mg oral tablet |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Stimulant (substance) |
Inferred relationship |
Some |
|
| Pemoline 75 mg oral tablet |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Stimulant (substance) |
Inferred relationship |
Some |
|
| Modafinil 200mg tablet |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Stimulant (substance) |
Inferred relationship |
Some |
|
| Phentermine hydrochloride 37.5 mg oral tablet |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Stimulant (substance) |
Inferred relationship |
Some |
|
| Product containing precisely phentermine hydrochloride 37.5 milligram/1 each conventional release oral capsule (clinical drug) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Stimulant (substance) |
Inferred relationship |
Some |
|
| Caffeine 30 mg and dihydrocodeine tartrate 16 mg and paracetamol 356.4 mg oral capsule |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Stimulant (substance) |
Inferred relationship |
Some |
|
| Product containing precisely aspirin 325 milligram and butalbital 50 milligram and caffeine 40 milligram/1 each conventional release oral capsule (clinical drug) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Stimulant (substance) |
Inferred relationship |
Some |
|
| Aspirin 325 mg and butalbital 50 mg and caffeine 40 mg oral tablet |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Stimulant (substance) |
Inferred relationship |
Some |
|
| Product containing precisely aspirin 356.4 milligram and caffeine 30 milligram and dihydrocodeine tartrate 16 milligram/1 each conventional release oral capsule (clinical drug) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Stimulant (substance) |
Inferred relationship |
Some |
|
| Aspirin 385 mg and caffeine 30 mg and orphenadrine citrate 25 mg oral tablet |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Stimulant (substance) |
Inferred relationship |
Some |
|
| Aspirin 428 mg and caffeine 30 mg and orphenadrine citrate 25 mg oral tablet |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Stimulant (substance) |
Inferred relationship |
Some |
|
| Product containing precisely caffeine 60 milligram and dihydrocodeine tartrate 32 milligram and paracetamol 712.8 milligram/1 each conventional release oral tablet (clinical drug) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Stimulant (substance) |
Inferred relationship |
Some |
|
| Aspirin 770 mg and caffeine 60 mg and orphenadrine citrate 50 mg oral tablet |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Stimulant (substance) |
Inferred relationship |
Some |
|
| Aspirin 856 mg and caffeine 60 mg and orphenadrine citrate 50 mg oral tablet |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Stimulant (substance) |
Inferred relationship |
Some |
|
| Aspirin 389 mg and caffeine 32.4 mg and dextropropoxyphene hydrochloride 65 mg oral capsule |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Stimulant (substance) |
Inferred relationship |
Some |
|
| Product containing precisely caffeine 100 milligram and isometheptene mucate 65 milligram and paracetamol 325 milligram/1 each conventional release oral capsule (clinical drug) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Stimulant (substance) |
Inferred relationship |
Some |
|
| Caffeine + ergotamine tartrate 100mg/1mg tablet |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Stimulant (substance) |
Inferred relationship |
Some |
|
| Caffeine + ergotamine tartrate 100mg/2mg suppository (product) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Stimulant (substance) |
Inferred relationship |
Some |
|
| Product containing precisely butalbital 50 milligram and caffeine 40 milligram and paracetamol 325 milligram/1 each conventional release oral capsule (clinical drug) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Stimulant (substance) |
Inferred relationship |
Some |
|
| Product containing precisely butalbital 50 milligram and caffeine 40 milligram and paracetamol 325 milligram/1 each conventional release oral tablet (clinical drug) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Stimulant (substance) |
Inferred relationship |
Some |
|
| Product containing precisely butalbital 50 milligram and caffeine 40 milligram and paracetamol 500 milligram/1 each conventional release oral capsule (clinical drug) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Stimulant (substance) |
Inferred relationship |
Some |
|
| Product containing precisely butalbital 50 milligram and caffeine 40 milligram and paracetamol 500 milligram/1 each conventional release oral tablet (clinical drug) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Stimulant (substance) |
Inferred relationship |
Some |
|
| phenterminhydrochlorid 15 mg kapsel med modificeret udløsning |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Stimulant (substance) |
Inferred relationship |
Some |
|
| acetylsalicylsyre + caffein + orphenadrincitrat tablet |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Stimulant (substance) |
Inferred relationship |
Some |
|
| Product containing caffeine in oral dose form (medicinal product form) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Stimulant (substance) |
Inferred relationship |
Some |
|
| Caffeine-containing product in rectal dose form |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Stimulant (substance) |
Inferred relationship |
Some |
|
| Product containing caffeine in parenteral dose form (medicinal product form) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Stimulant (substance) |
Inferred relationship |
Some |
|
| phentermin kapsel med modificeret udløsning |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Stimulant (substance) |
Inferred relationship |
Some |
|
| Product containing phentermine in oral dose form (medicinal product form) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Stimulant (substance) |
Inferred relationship |
Some |
|
| Product containing phendimetrazine (medicinal product) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Stimulant (substance) |
Inferred relationship |
Some |
|
| analeptisk middel |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Stimulant (substance) |
Inferred relationship |
Some |
|
| Product containing phentermine (medicinal product) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Stimulant (substance) |
Inferred relationship |
Some |
|
| Product containing pemoline (medicinal product) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Stimulant (substance) |
Inferred relationship |
Some |
|
| psykostimulerende middel |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Stimulant (substance) |
Inferred relationship |
Some |
|
| Product containing caffeine (medicinal product) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Stimulant (substance) |
Inferred relationship |
Some |
|
| Product containing prolintane (medicinal product) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Stimulant (substance) |
Inferred relationship |
Some |
|
| koffein og natriumbenzoat injektionsvæske, opløsning, hætteglas |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Stimulant (substance) |
Inferred relationship |
Some |
|
| Butalbital 50 mg and caffeine 40 mg and codeine phosphate 30 mg and paracetamol 325 mg oral capsule |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Stimulant (substance) |
Inferred relationship |
Some |
|
| Aspirin 325 mg and butalbital 50 mg and caffeine 40 mg and codeine phosphate 30 mg oral capsule |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Stimulant (substance) |
Inferred relationship |
Some |
|
| acetylsalicylsyre + butalbital + caffein + codeinphosphat |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Stimulant (substance) |
Inferred relationship |
Some |
|
| paracetamol + caffein + isometheptenmucat |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Stimulant (substance) |
Inferred relationship |
Some |
|
| acetylsalicylsyre + caffein + propoxyphenhydrochlorid |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Stimulant (substance) |
Inferred relationship |
Some |
|
| acetylsalicylsyre + caffein + dihydrocodeinbitartrat |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Stimulant (substance) |
Inferred relationship |
Some |
|
| Caffeine + ergotamine tartrate |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Stimulant (substance) |
Inferred relationship |
Some |
|
| Product containing caffeine and sodium benzoate (medicinal product) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Stimulant (substance) |
Inferred relationship |
Some |
|
| Product containing butalbital and caffeine and paracetamol (medicinal product) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Stimulant (substance) |
Inferred relationship |
Some |
|
| acetylsalicylsyre + caffein + orphenadrincitrat |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Stimulant (substance) |
Inferred relationship |
Some |
|
| paracetamol + butalbital + caffein + codeinphosphat |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Stimulant (substance) |
Inferred relationship |
Some |
|
| Product containing aspirin and butalbital and caffeine (medicinal product) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Stimulant (substance) |
Inferred relationship |
Some |
|
| doxapramhydrochlorid 20 mg/ml injektionsvæske, opløsning, ampul a 5 ml |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Stimulant (substance) |
Inferred relationship |
Some |
|
| Product containing precisely caffeine 100 milligram and ergotamine tartrate 1 milligram/1 each conventional release oral tablet (clinical drug) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Stimulant (substance) |
Inferred relationship |
Some |
|
| Caffeine 100 mg and ergotamine tartrate 2 mg rectal suppository |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Stimulant (substance) |
Inferred relationship |
Some |
|
| Methylphenidate hydrochloride 10 mg oral tablet |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Stimulant (substance) |
Inferred relationship |
Some |
|
| Methylphenidate hydrochloride 5 mg oral tablet |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Stimulant (substance) |
Inferred relationship |
Some |
|
| Methylphenidate hydrochloride 20 mg oral tablet |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Stimulant (substance) |
Inferred relationship |
Some |
|
| Product containing methyltestosterone and pemoline and yohimbine (medicinal product) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Stimulant (substance) |
Inferred relationship |
Some |
|
| Product containing precisely methyltestosterone 5 milligram and pemoline 10 milligram and yohimbine 5 milligram/1 each conventional release oral capsule (clinical drug) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Stimulant (substance) |
Inferred relationship |
Some |
|
| doxapramhydrochlorid 2 mg/ml infusionsvæske, opløsning, flaske a 500 ml |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Stimulant (substance) |
Inferred relationship |
Some |
|
| Product containing methylphenidate (medicinal product) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Stimulant (substance) |
Inferred relationship |
Some |
|
| Product containing doxapram (medicinal product) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Stimulant (substance) |
Inferred relationship |
Some |
|
| paracetamol + caffein + dihydrocodeinbitartrat |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Stimulant (substance) |
Inferred relationship |
Some |
|
| Doxapram hydrochloride [respiratory use] |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Stimulant (substance) |
Inferred relationship |
Some |
|
| Doxapram HCl [anesthesia] |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Stimulant (substance) |
Inferred relationship |
Some |
|
| methylphenidathydrochlorid 20 mg kapsel med modificeret udløsning |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Stimulant (substance) |
Inferred relationship |
Some |
|
| Modafinil 200 mg oral tablet |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Stimulant (substance) |
Inferred relationship |
Some |
|
| methylphenidathydrochlorid 18 mg tablet med modificeret udløsning |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Stimulant (substance) |
Inferred relationship |
Some |
|
| methylphenidathydrochlorid 36 mg tablet med modificeret udløsning |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Stimulant (substance) |
Inferred relationship |
Some |
|
| methylphenidathydrochlorid med modificeret udløsning |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Stimulant (substance) |
Inferred relationship |
Some |
|
| dexmethylphenidat |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Stimulant (substance) |
Inferred relationship |
Some |
|
| Dexmethylphenidate hydrochloride 2.5 mg oral tablet |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Stimulant (substance) |
Inferred relationship |
Some |
|
| Dexmethylphenidate hydrochloride 5 mg oral tablet |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Stimulant (substance) |
Inferred relationship |
Some |
|
| Dexmethylphenidate hydrochloride 10 mg oral tablet |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Stimulant (substance) |
Inferred relationship |
Some |
|
| Methylphenidate-containing product in oral dose form |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Stimulant (substance) |
Inferred relationship |
Some |
|
FHIR